Navigation Links
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Date:10/23/2007

Positive Results Prompt Phase 2 Trial of JX-594 in Liver and Head and Neck

Cancers

SAN FRANCISCO, Oct. 23 /PRNewswire/ -- Jennerex Biotherapeutics today presented clinical data from a Phase 1 / 2 trial of JX-594 -- the company's proprietary targeted lytic and immunostimulatory armed virus therapy -- demonstrating objective evidence of efficacy in 10 of the 13 evaluable patients with advanced treatment-refractory tumors in the liver (primary and metastatic). Responses were particularly encouraging in primary liver (HCC) cancers, squamous cell cancers (including lung) and melanoma. All three patients with primary liver cancer had evidence of efficacy, including tumor marker decreases of 65, 80 and 98 percent.

Seven patients survived for at least eight months (double the life expectancy), and four are still alive up to 17 months post-treatment; two are alive over one year. Importantly, JX-594 was shown to be generally well tolerated in the Phase 1 / 2 study. These data were presented today by David H. Kirn, M.D., CEO and President of Jennerex at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in San Francisco, California.

"We are extremely encouraged by these results, particularly with respect to the effectiveness of JX-594 against liver cancers and squamous cell cancers including lung cancer," said Herbert M. Pinedo, M.D., board member and former president of the European Society of Medical Oncology.

"The survival of many of these patients is remarkable, in particular those who had major tumor responses. This has great promise for many cancer types, starting with liver and head and neck cancers," said the study's principal investigator, Dr. B-H Park, Chief, Interventional Radiology, DAU University, South Korea.

Following on these results, Jennerex is initiating a Phase 2a clinical trial in the United States for hepatocellular (liver) carcinoma at leading cancer centers including the University of Pittsburgh and the University of California, San Diego. Jennerex is planning to initiate a Phase 2a for squamous cell head and neck cancers in early 2008. The company also plans to conduct clinical trials for patients with lung cancer and melanoma.

"The broad clinical efficacy reported by these investigators strongly validates this first-in-class product, JX-594, and its novel mechanism-of-action. These exciting clinical results mirror closely what has been reported in preclinical studies," said David H. Kirn, M.D., CEO and President of Jennerex. "We are extremely grateful for the support of our clinical collaborators, as well as for the sponsorship of our partners for South Korea at Green Cross Corporation."

"We are very pleased to be collaborating with Jennerex for the development of this kind of exciting new drug, JX-594, in Korea," said B.G. Rhee, Ph.D., executive vice president of Green Cross. Jennerex has an exclusive partnership with Green Cross for the South Korean market only.

About JX-594

Jennerex's lead product candidate, JX-594, is a genetically-engineered vaccinia virus strain that is uniquely suited to treat cancers. It is designed to destroy both injected and non-injected metastatic tumors.

About Jennerex

Jennerex Biotherapeutics is a clinical stage biotherapeutics company working to create, develop and commercialize first-in-class cancer products. The company's products are engineered viruses that have been modified to be safe and effective against various forms of cancer. Jennerex products seek to kill cancer by targeting, attacking and eradicating cancer cells. The company's lead product candidate, JX-594, demonstrated clear anti-cancer effects in patients in a Phase 1 / 2 clinical trial. A Phase 2a clinical trial for liver cancer is currently being initiated. A Phase 2 trial for JX-594 in squamous cell head and neck cancer is expected to begin in the first quarter of 2008. JX-594 is the first of a novel class of therapeutic products engineered to target, attack and eradicate cancers.

For more information about Jennerex, please visit http://www.jennerex.com.

About Green Cross Corporation

Green Cross is a leader in the Korean biotechnology and pharmaceutical industries. Green Cross is now an internationally recognized biotechnology company developing several vaccines and therapeutic proteins. Green Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed one of the earliest vaccines against Hepatitis B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green Cross is developing anticancer drugs such as Greenstatin (anti-angiogenic peptide) and modified PEG-G-CSF for neutropenia. For more information about Green Cross, please visit http://www.greencross.com.

Contact:

Jennerex Biotherapeutics

Ian W. Malone

Chief Financial Officer

Office: 613-730-8019

Mobile: 613-612-8019

Email: imalone@jennerex.com


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):